Phase 2 N=30 Sodium Nitrite in Acute Myocardial Infarction
Acute Myocardial Infarction
Primary: Ischemia Area at Risk as Determined by Paired Single-photon Computed Tomography Studies With Technetium Tc99m Sestamibi.
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=452 The INFUSE - Anterior Myocardial Infarction (AMI) Study
Acute Anterior Myocardial Infarction
Primary: Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion — 15.1; 17.9; 17.2 Percentage of Left…
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 3 N=3,506 Myocardial Ischemia and Transfusion
Myocardial Infarction · Anemia
Primary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants
Phase 3 N=380 Metformin to Reduce Heart Failure After Myocardial Infarction
ST Elevation Myocardial Infarction (STEMI) · Coronary Artery Disease · Heart Failure
Primary: Improvement in Left Ventricular Ejection Fraction — 53.1; 54.8 % of LVEF
Phase 2 N=120 A Study of Acute Myocardial Infarction Using FDY-5301
Acute Myocardial Infarction · STEMI
Primary: Arrhythmias of Interest, 48 Hours (Overall) — 0; 0; 0; 0 participants
Phase 4 N=104 Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Myocardial Infarction · Reperfusion Injury
Primary: Cardiac Death — 0; 0 events
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=3,000 Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Resulting in Myocardial Infarction
Myocardial Infarction · Acute Coronary Syndrome · Coronary Artery Disease
Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants
Phase 2 N=106 Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
Acute Myocardial Infarction
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 28; 30; 31; 14 Participants
N/A N=105 Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion
ST Elevation Myocardial Infarction
Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units
Phase 2 N=526 A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Acute Coronary Syndrome
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 97; 138; 131; 269 Participants
Phase 2 N=126 Post-Myocardial Infarction Remodeling Prevention Therapy
Acute Myocardial Infarction · Pacing Therapy · Cardiac Remodeling
Primary: Change in Left Ventricular End Diastolic Volume (LVEDV) — 16.4; 15.8 mL
N/A N=242 Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI
Multi Vessel Coronary Artery Disease · STEMI
Primary: Composite of: Cardiovascular Death*, Re-myocardial Infarct, Re-hospitalization for Heart Failure (HF) and Congestive Heart Failure (CHF), Resuscitation or ICD…
Phase 2 N=30 Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Acute Myocardial Infarction · Heart Failure
Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05
N/A N=4,695 Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
COVID-19 · Myocardial Reperfusion Injury · Cardiovascular Diseases
Primary: Number of Death — 417; 137; 552 Participants
Phase 3 N=476 Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
Acute Myocardial Infarction
Primary: Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels — -84.9; -82.2 pg/mL
Phase 3 N=40 Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Heart Disease, Ischemic · Atherosclerosis, Coronary
Primary: Magnetic Resonance Image Quality Rating — 3.57; 2.55 units on a likert scale — p=<0.001
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
Phase 3 N=110 Myocardial Ischemia and Transfusion Pilot
Myocardial Infarction · Unstable Angina · Coronary Artery Disease
Primary: Hemoglobin Concentration — 10.30; 9.03; 10.78; 8.98 g/dL — p=<0.001
Phase 2 N=423 Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
Coronary Heart Disease (CHD)
Primary: Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA)…
Phase 3 N=911 IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
Angina, Unstable · Cardiovascular Diseases · Heart Diseases
Primary: Progression of Acute Coronary Syndrome to Myocardial Infarction — 200; 242 participants — p=0.28
Phase 2 N=593 A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size
N/A N=18 Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy
Heart Transplantation
Primary: Correlation Co-efficient Between MRS Spectroscopy and Endomyocardial Biopsy in Heart Transplant Participants — 0.97 correlation co-efficient — p=<0.05
Phase 2 N=31 REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
Acute ST Elevation Myocardial Infarction
Primary: Infarct Size in the Territory of the Infarct Related Artery — 15.8; 15.0 percentage of LV mass
Phase 2 N=295 Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Myocardial Infarction
Primary: Left Ventricular Ejection Fraction Assessed by Cardiac Magnetic Resonance Imaging (CMRI) — 5.6; 5.3; 5.7 percentage of left ventricular volumes
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
Phase 2 N=103 Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
Acute Myocardial Infarction
Primary: Infarct Size on Baseline Cardiac Magnetic Resonance Imaging (cMRI) — 20.1; 21.0 ml — p=0.90
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
N/A N=119 Myocardial Injury and Quality of Life After COVID-19
COVID-19 · Myocardial Injury · Myocarditis Post Infection
Primary: Percentage of Patients (%) Recovered From COVID-19 With a Decrease in the Global Contractility of the Left and Right Ventricles. — 19; 39; 48 Participants